COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Authors:
- Livio PaganoLPLivio Pagano
- Jon Salmanton-GarcíaJSJon Salmanton-García
- Francesco MarchesiFMFrancesco Marchesi
- Alberto López-GarcíaAlberto López-García
- Sylvain LamureSLSylvain Lamure
- Federico ItriFIFederico Itri
- Maria Gomes-SilvaMGMaria Gomes-Silva
- Giulia DragonettiGDGiulia Dragonetti
- Iker Falces-RomeroIFIker Falces-Romero
- Jaap van DoesumJDJaap van Doesum
- Uluhan SiliUSUluhan Sili
- Jorge LabradorJLJorge Labrador
Open Access
- 10 March 2022
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 139 (10) , 1588-1592
Abstract
In a Plenary Paper, Mittelman and colleagues assess the relative clinical efficacy of mRNA vaccination on COVID-19 disease incidence and outcomes in patients with hematologic malignancies compared with healthy matched controls. This population-based study from Israel links prior observations of poor serologic responses to vaccination to higher risk for breakthrough infection, hospitalization, and death in patients with blood cancer, especially those on active antineoplastic therapy. In an accompanying Letter to Blood, Pagano et al provide supportive data using a multination survey approach to capture outcomes for COVID-19 in vaccinated patients with hematologic neoplasms. They also emphasize the higher risk among patients with lymphoid malignancies. Together, these findings argue for both continued deployment of booster programs and ongoing public health guidance for this vulnerable group.Keywords
This publication has 22 references indexed in Scilit:
- COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective surveyLeukemia, 2021
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institutionJournal of Hematology & Oncology, 2021
- Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaBlood, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsNew England Journal of Medicine, 2020
- Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data HubBlood Advances, 2020
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort studyThe Lancet Haematology, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- 2017 ECIL 7 vaccine guidelinesThe Lancet Infectious Diseases, 2019
- Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised studyBritish Journal of Haematology, 2005